| Full text | |
| Author(s): |
de Lima Marson, Fernando Augusto
[1, 2]
;
Russo Hortencio, Tais Daiene
[2]
;
Alberto Aguiar, Katia Cristina
[2]
;
Ribeiro, Jose Dirceu
[2]
;
Grp, CYFIUC
Total Authors: 5
|
| Affiliation: | [1] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Med Genet, Campinas, SP - Brazil
[2] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Pediat, Campinas, SP - Brazil
Total Affiliations: 2
|
| Document type: | Journal article |
| Source: | BMC PULMONARY MEDICINE; v. 15, JAN 15 2015. |
| Web of Science Citations: | 9 |
| Abstract | |
Background: In recent years, patients with cystic fibrosis (CF) have tended to experience a longer life expectancy and higher quality of life. In this context, the aim of the present study was to evaluate and compare the demographic, clinical, and laboratory markers of patients with CF during the last two decades at a CF referral center. Methods: A retrospective study of the demographic, clinical, and laboratory markers for CF treatment at a CF referral center was performed during two decades: 2000 (DI, 1990-2000, n = 104 patients) and 2010 (DII, 2000-2010, n = 181 patients). Results: The following variables were less common in DI than in DII: (i) pancreatic insufficiency, (ii) meconium ileus, (iii) diabetes mellitus, (iv) Burkholderia cepacia colonization, (v) moderate and severe Shwachman-Kulczycki score (SKS), (vi) F508del mutation screening, (vii) patients without an identified CFTR mutation (class IV, V, or VI mutation), (viii) patients above the 10th percentile for weight and height, (ix) restrictive lung disease, and (x) older patients (p < 0.01). The following variables were more common in DI than in DII: (i) excellent and good SKS, (ii) F508del heterozygous status, (iii) colonization by mucoid and nonmucoid Pseudomonas aeruginosa, iv) obstructive lung disease, and (v) minimal time for CF diagnosis (p < 0.01). Conclusion: Clinical outcomes differed between the two decades. Demographic, clinical, and laboratory markers in patients with CF are useful tools and should be encouraged in CF referral centers to determine the results of CF management and treatment, enabling a better understanding of this disease and its clinical evolution. Early diagnosis and management of CF will improve patients' quality of life and life expectancy until personalized drug therapy is possible for all patients with CF. (AU) | |
| FAPESP's process: | 11/12939-4 - Association between polymorphisms in modifier genes in children and adolescent with allergic and non-allergic: mild, moderate and severe asthma |
| Grantee: | Fernando Augusto de Lima Marson |
| Support Opportunities: | Scholarships in Brazil - Doctorate |